WuXi Biologics (300142.SZ): Freeze-dried herpes simplex virus mRNA vaccine approved for clinical trials

The Zhitong Financial APP news reported that Watson Biotech (300142.SZ) announced that its subsidiaries Beijing Watson Innovative Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., Yuxi Watson Biotechnology Co., Ltd., in conjunction with Fudan University and Shanghai Lanque Biopharmaceutical Co., Ltd. ("Lanque Biopharmaceutical"), have jointly developed and applied for clinical trials of freeze-dried herpes zoster virus mRNA vaccines. Recently, they have obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. After review, the freeze-dried herpes zoster virus mRNA vaccine, which was accepted on September 18, 2025, meets the relevant requirements for drug registration, and clinical trials for the prevention of herpes zoster are approved.